Analgesic Border Adhesive for Wound Dressing Pain Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wound dressings can cause pain due to adherence and removal, and negative-pressure therapy can exacerbate discomfort, particularly with wound edge contraction, necessitating improved pain management solutions.
Innovation Solution
A wound dressing with an analgesic border adhesive, where the analgesic is delivered to the periwound skin while preventing contact with the wound, using a drug-blocking layer and a therapeutic composition comprising at least 20% analgesic, suitable for negative-pressure therapy and available in various configurations including tapes and strips.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adhesive is applied to periwound skin to secure dressing, then dressing stability is improved, but pain during application and removal worsens
Solution Approach 1:
The adhesive is formulated with analgesic properties specifically at the border region where it contacts periwound skin, creating a localized pain-relieving effect precisely where the harmful adhesive contact occurs, while maintaining secure bonding to the skin surface
Solution Approach 2:
A drug-blocking layer is introduced as an intermediary component between the adhesive and the wound. This layer allows the adhesive to bond to periwound skin while preventing analgesic delivery to the wound bed, and also serves as a pain-relieving interface during dressing application and removal
2Productivity
If negative-pressure therapy is applied to promote wound healing, then tissue regeneration is improved, but pain at wound edge worsens
Solution Approach 1:
The analgesic adhesive is applied to the periwound skin before negative-pressure therapy begins, pre-establishing a pain-relieving barrier that protects against the mechanical stress and contraction pains that will occur during subsequent wound healing and dressing changes
Solution Approach 2:
The analgesic effect is localized to the periwound skin region through the border-specific adhesive formulation and drug-blocking layer, providing pain relief exactly where negative-pressure therapy causes the most discomfort (at the wound edge) without interfering with the therapeutic pressure application to the wound bed
3Object-affected harmful factors
If analgesic is delivered to periwound skin to reduce pain, then patient comfort is improved, but risk of analgesic exposure to wound worsens
Solution Approach 1:
The drug-blocking layer acts as a selective intermediary that permits the analgesic to reach and benefit the periwound skin while simultaneously blocking its migration to the wound bed, thus achieving pain relief without the harmful side effect of wound exposure to analgesics
Solution Approach 2:
The adhesive system is segmented into distinct functional zones: an outer border region containing the analgesic for periwound pain relief, and an inner region with drug-blocking properties that prevents analgesic contact with the wound, allowing each zone to perform its specific function independently
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The analgesic border adhesive effectively reduces pain during dressing wear and removal, enhancing patient comfort and therapy efficacy by targeting periwound skin without exposing the wound to analgesics, particularly beneficial for negative-pressure therapy.
Implementation Method 1
The wound interface layer may be a foam, that provides a drug-blocking layer between the analgesic adhesive and the wound interface layer. The drug-blocking layer can prevent the analgesic from being delivered to a wound, while allowing delivery to the periwound skin.
Data Source
Figure 1
Figure 2A~3B
AI summary
A dressing may comprise a backing layer having an interior region and a border region around the interior region. A dermal interface may be disposed in the border region. The dermal interface may comprise an adhesive and a therapeutic composition, such as a topical analgesic. The therapeutic composition may be dissolved into the adhesive, and preferably constitutes at least 20 percent of the dermal interface. In some embodiments, the therapeutic composition may comprise at least 30 percent of the dermal interface.